GLP-2 TIRZUnderstand the science
Which two receptors recognize tirzepatide?
1 numbered sourceSource years 2022
Peptides are short chains of amino acids connected by peptide bonds. The order of those amino acids can help determine which receptors recognize a peptide. Tirzepatide is designed to activate the receptors for glucose-dependent insulinotropic polypeptide, called GIP, and glucagon-like peptide-1, called GLP-1. The “GLP-2” part of the catalog label refers to the label alone. For the specific question of how tirzepatide engages the two receptors, an older structural study supplies direct evidence. [1]
Incretins are signals released from the gut that help regulate blood glucose after meals. GIP and GLP-1 act through separate receptors. The researchers used cryogenic electron microscopy to examine tirzepatide associated with each receptor. They also ran computer simulations to study how the peptide and receptors could move. These approaches can show which parts of a molecule lie near one another and help explain why a designed peptide gives different signals through different receptors. [1]
The authors found that tirzepatide’s activation of the GIP receptor resembled features of how native GIP acts there. Its interaction with the GLP-1 receptor had important differences from native GLP-1. The study also examined the role of the peptide’s attached fatty acid alongside its amino-acid sequence. The work gives a molecular account of how one designed chain can engage two related receptors in distinct ways. [1]
These structures and laboratory responses clarify the target names. They provide no estimate of average weight change, blood sugar or side effects in a clinical trial. Human outcomes require comparisons in people. The molecular work helps explain what investigators mean when they call tirzepatide a dual incretin receptor agonist. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
